Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors.
Akihito KawazoeYasutoshi KubokiHideaki BandoShota FukuokaTakashi KojimaYoichi NaitoShuichi IinoYasuhide YodoToshihiko DoiKohei ShitaraTakayuki YoshinoPublished in: Cancer chemotherapy and pharmacology (2020)
Napabucasin was well-tolerated at doses up to 1440 mg/day in Japanese patients with advanced solid tumors; the PK profile was comparable to that reported previously.